Previous 10 | Next 10 |
SAN DIEGO, June 29, 2020 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company developing long-acting therapeutics to transform the standard of care for patients facing serious fungal or viral infections, today announced that it has been added to the Russell ...
SAN DIEGO, June 23, 2020 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company developing long-acting therapeutics to transform the standard of care for patients facing serious fungal or viral infections, today announced that Jeffrey Stein, Ph.D., President a...
SAN DIEGO, June 11, 2020 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company developing long-acting therapeutics to transform the standard of care for patients facing serious fungal or viral infections, today announced that Jeffrey Stein, Ph.D., President a...
AstraZeneca and Merck Receive Lynparza Boost AstraZeneca ( AZN ) and Merck & Co. ( MRK ) announced that their Lynparza has received the FDA nod for its fourth tumor type, prostate cancer. This PARP inhibitor is now authorized to be used for treating patients with previously treated m...
The first patient has been dosed in a pivotal 462-subject Phase 3 clinical trial, ReSPECT , evaluating Cidara Therapeutics' ( CDTX +0.9% ) lead candidate rezafungin for the prevention of invasive fungal disease in patients undergoing allogeneic blood and marrow transplantation. More...
SAN DIEGO and CAMBRIDGE, England, May 20, 2020 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company developing long-acting therapeutics to transform the standard of care for patients facing serious fungal or viral infections, and Mundipharma today announced ...
Cidara Therapeutics (NASDAQ: CDTX ): Q1 GAAP EPS of -$0.46 misses by $0.12 . More news on: Cidara Therapeutics, Inc., Earnings news and commentary, Healthcare stocks news, , Read more ...
SAN DIEGO, May 13, 2020 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company developing long-acting therapeutics to transform the standard of care for patients facing serious fungal or viral infections, today reported financial results for the three months e...
The following slide deck was published by Cidara Therapeutics, Inc. in conjunction with this Read more ...
Abstract Book highlights new data from Cidara accepted for presentation at ECCMID 2020 Phase 2 trial shows superiority of rezafungin in time to clear deadly infection Seven abstracts highlight new data on influenza antiviral conjugates (AVCs) from Cloudbreak® antiviral ...
News, Short Squeeze, Breakout and More Instantly...
Cidara Therapeutics Inc. Company Name:
CDTX Stock Symbol:
NASDAQ Market:
Cidara Therapeutics Inc. Website:
2024-07-16 23:12:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
SAN DIEGO, May 30, 2024 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company using its proprietary Cloudbreak ® platform to develop drug-Fc conjugate (DFC) immunotherapies designed to save lives and improve the standard of care for patients facing serious...
SAN DIEGO, May 15, 2024 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (Nasdaq: CDTX) (the Company), a biotechnology company using its proprietary Cloudbreak ® platform to develop drug-Fc conjugate (DFC) immunotherapies designed to save lives and improve the standard of care for patients ...